Skip to content

Role of Homoeopathy in the treatment of chronic urticaria

Different homoeopathic potency scales in management of cases of chronic urticaria a comparative study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/06/043474
Enrollment
60
Registered
2022-06-24
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L50- Urticaria

Interventions

Intervention1: homoeopathic medicine in centesimal scale and fifty millesimal scale: Group A Homoeopathic medicine in centesimal scale Indicated medicine will be given orally One drachm phial with 4

Sponsors

Bakson Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age 18 to 59 years 2 Both male and female 3 Patients of chronic Urticaria more than 6 weeks duration of suffering 4 Patients suffering from chronic urticaria diagnosis as per EAACI GA2LEN EDF WAO International Guidelines for urticaria 5 wheal in patients with urticaria has 3 typical features 6 a central swelling of variable size almost invariably surrounded by reflex erythema 7 an itching or sometimes burning sensation A fleeting nature with the skin returning to its normal appearance usually within 30 minutes to 24 hours 8 Angioedema in urticaria patients is characterized by A sudden pronounced erythematous or skin color swelling of the lower dermis and subcutis or mucous membrane 9 Sometimes pain rather than itching. A resolution slower than that of wheals (can take up to 72 hours 10 Patients already on allopathic medication or topical agents for chronic urticaria will be included after a washout period of 15 days

Exclusion criteria

Exclusion criteria: 1 Below 18 years and above 59 years 2 Acute Urticaria less than 6 weeks of suffering 3 Alcohol or drug addiction 4 Angioedema with no urticaria 5 Urticarial vasculitis 6 Maculopapular drug eruption 7 Contact dermatitis 8 Urticaria pigmentosa 9 Pregnant and lactating women 10 Patients with psychiatric diseases, and those who are not able to comply with the study protocol

Design outcomes

Primary

MeasureTime frame
There will be difference between result of Centesimal potencies and Fifty millesimal potencies which are used in managing the cases of chronic urticariaTimepoint: follow up in 15 days

Secondary

MeasureTime frame
There will be reduction in UAS 7 score Timepoint: follow up in every 15 days

Countries

India

Contacts

Public ContactProf Dr C P Sharma

Bakson Homoeopathic Medical College and Hospital

principal@bakson.net9899101747

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026